Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy, Biologic therapy.

National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Bethesda, Maryland
Treatments:Chemotherapy, Biologic therapyHospital:National Cancer Institute, National Institutes of Health
Drugs:Journal:Link
Date:Jul 2004

Description:

Patients: This Phase II trial involved a total of 75 patients with hormone refractory (androgen-independent) prostate cancer. Patients were divided into two groups: Group 1 comprised of 25 patients and Group 2 comprised of 50 patients. The median age for patients in Group 2 was 71 years and the median baseline PSA was 59.9 (range 2 – 1,777).

Treatment: For patients in Group 2, the treatment consisted of the chemotherapy drug, docetaxel (taxotere) plus the anti-angiogenesis drug, thalidomide (thalomid).

Toxicity: For patients in Group 2, grade 3 toxicities included fatigue, allergic reaction, depression, thrombosis, hyperglycemia, thrombocytopenia, neutropenia, and anemia.

Results: For patients in Group 2 the median survival was 28.9 months.

Correspondence: William D. Figg, MD





Back